Correction: Cardiorenal effectiveness of empagliflozin vs. glucagon-like peptide-1 receptor agonists: final-year results from the EMPRISE study
Main Authors: | Phyo T. Htoo, Helen Tesfaye, Sebastian Schneeweiss, Deborah J. Wexler, Brendan M. Everett, Robert J. Glynn, Niklas Schmedt, Lisette Koeneman, Anouk Déruaz-Luyet, Julie M. Paik, Elisabetta Patorno |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2024-03-01
|
Series: | Cardiovascular Diabetology |
Online Access: | https://doi.org/10.1186/s12933-024-02190-6 |
Similar Items
-
Cardiorenal effectiveness of empagliflozin vs. glucagon-like peptide-1 receptor agonists: final-year results from the EMPRISE study
by: Phyo T. Htoo, et al.
Published: (2024-02-01) -
Empagliflozin is associated with lower risk of cardiovascular events and all‐cause mortality in routine care in East Asia: Results from the EMPRISE study
by: Dae Jung Kim, et al.
Published: (2023-03-01) -
Empagliflozin is associated with lower cardiovascular risk compared with dipeptidyl peptidase-4 inhibitors in adults with and without cardiovascular disease: EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) study results from Europe and Asia
by: Dorte Vistisen, et al.
Published: (2023-08-01) -
Villes et diasporas : emprises, empreintes, expériences
by: Anouche Kunth
Published: (2016-12-01) -
‘Évaluer l’évaluation. Emprises, déploiements, subversions.’
by: Le Comité de Rédaction d' EspacesTemps
Published: (2005-11-01)